POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
Rhea-AI Summary
Pomdoctor (NASDAQ:POM) reported fiscal 2025 net revenues of RMB399.9 million, up 16.7% year over year, and gross profit of RMB52.3 million, up 9.6%.
Net loss widened to RMB130.9 million, driven mainly by higher operating expenses, including IPO- and investor-relations-related professional fees, while Internet hospital revenue rose 69.3%.
The company completed a Nasdaq IPO in October 2025, raising gross proceeds of US$23.0 million.
Positive
- Net revenues grew 16.7% to RMB399.9 million in fiscal 2025
- Internet hospital revenue increased 69.3% to RMB150.7 million
- Online pharmacy sales rose from RMB87.8 million to RMB149.2 million
- Gross profit increased 9.6% to RMB52.3 million
- R&D spending increased 328.5% to RMB12.9 million, focused on AI healthcare
- Completed Nasdaq IPO raising US$23.0 million in gross proceeds
- Financing cash inflow rose to RMB153.9 million from RMB17.0 million
Negative
- Net loss expanded to RMB130.9 million from RMB37.4 million
- Total operating expenses rose to RMB170.9 million from RMB73.5 million
- Operating cash outflow increased to RMB148.5 million from RMB16.1 million
- Gross margin declined to 13.1% from 13.9%
- Internet hospital gross margin fell to 32.7% from 42.7%
- Pharmaceutical supply chain gross margin decreased to 1.2% from 3.8%
- Pharmaceutical supply chain revenue declined 1.7% to RMB249.2 million
- General and administrative expenses rose 402.9% to RMB59.7 million
News Market Reaction – POM
In the May 15 session, POM declined 3.33%, reflecting a moderate negative market reaction. Argus tracked a peak move of +15.8% during that session. Argus tracked a trough of -22.5% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Earnings results | Neutral | -3.5% | Unaudited H1 2025 results with revenue growth but continued net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited earnings history shows the prior earnings release on Dec 03, 2025 drew a -3.46% move despite revenue growth, suggesting past pressure around financial updates.
Recent news for POM highlights a mix of strategic and financial developments. On Dec 03, 2025, unaudited first-half fiscal 2025 results showed net revenue up 16.2% to RMB174.5 million and gross profit up 16.3% with a 16.2% margin, but a net loss of RMB19.9 million and cash of RMB5.7 million. That earnings release coincided with a -3.46% move. Subsequent releases detailed AI-focused upgrades, insurance integration, Nasdaq minimum-bid issues, and growing pharmaceutical partnerships, framing today’s full-year 2025 report as a continuation of growth-with-losses.
Key Terms
initial public offering financial
over-allotment option financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy. Both our net revenues and gross profit recorded solid year-over-year increases, by
"During the year, we also increased our investments in research and development ("R&D") by
"Despite the net loss for the year, which was primarily attributable to significant non-recurring expenses associated with our initial public offering, including professional service fees and investor relations initiatives, we view these costs as necessary and strategic investments. These investments enabled our transition to a publicly listed company, strengthened our corporate governance, enhanced our operational and financial capabilities, and unlocked broader growth opportunities for the future. Following our successful listing, we are now better positioned to access capital market resources to support business expansion and execute our long-term growth strategy more efficiently on a larger scale.
"Looking ahead, we remain confident in the long-term growth potential of
Fiscal Year 2025 Financial Summary
- Net revenues were RMB399.9 million (
US ) in fiscal year 2025, an increase of$57.2 million 16.7% from RMB342.6 million in fiscal year 2024. - Gross profit was RMB52.3 million (
US million) in fiscal year 2025, an increase of$7.5 9.6% from RMB47.7 million in fiscal year 2024. - Gross margin was
13.1% in fiscal year 2025, compared to13.9% in fiscal year 2024. - Net loss was RMB130.9 million (
US million) in fiscal year 2025, compared to RMB37.4 million in fiscal year 2024.$18.7 - Basic and diluted loss per share were RMB21.96 (
US .14) in fiscal year 2025, compared to$3 RMB22 .72 in fiscal year 2024.
Fiscal Year 2025 Financial Results
Net Revenues
Net revenues were RMB399.9 million (
- Net revenues from Internet hospital were
RMB150.7 million (US ) in fiscal year 2025, an increase of$21.6 million 69.3% fromRMB89.0 million in fiscal year 2024. The increase was primarily due to the increase in revenues generated from online pharmacy sales. In fiscal year 2025, the Company deepened cooperation with pharmacy manufacturers to sell their products through its Internet hospital platform, which led to that revenue from the Company's online pharmacy sales increased fromRMB87.8 million in fiscal year 2024 toRMB149.2 million (US ) in fiscal year 2025. Revenue from online consultation service slightly increased from$21.3 million RMB1.2 million in fiscal year 2024 toRMB1.5 million (US ) in fiscal year 2025.$0.2 million - Net revenues from pharmaceutical supply chain were
RMB249.2 million (US ) in fiscal year 2025, a decrease of$35.6 million 1.7% fromRMB253.5 million in fiscal year 2024, primarily driven by the decrease in the Company's pharmacy wholesale business fromRMB246.9 million in fiscal year 2024 toRMB243.2 million (US ) in fiscal year 2025, as a result of the Company's stable pharmaceutical supply chain business and reduction cooperation with the customers whose credit terms were relatively longer than others. Because of high competition of retail pharmacy store, two of the Company's retail sales stores were closed in fiscal year 2025, which led to that the revenues from pharmacy retail sales also decreased from$34.8 million RMB6.6 million in fiscal year 2024 toRMB6.0 million (US ) in fiscal year 2025.$0.9 million
Cost of Revenues
Cost of revenue was RMB347.6 million (
Gross Profit and Gross Margin
Gross profit was RMB52.3 million (
Gross margin was
- Gross profit margin of Internet hospital was
32.7% in fiscal year 2025, decreased from42.7% in fiscal year 2024. The decrease mainly attributable to the increase in the online pharmacy sales of products with lower gross profit margin. - Gross profit margin of pharmaceutical supply chain was
1.2% in fiscal year 2025, decreased from3.8% in fiscal year 2024. The decrease was primarily because the gross profit margin of the Company's pharmacy wholesale customers newly obtained in fiscal year 2025 was lower than that of customers in fiscal year 2024.
Operating Expenses
Total operating expenses were RMB170.9 million (
- Sales and marketing expenses were
RMB96.2 million (US ) in fiscal year 2025, increased by$13.8 million 70.7% fromRMB56.4 million in fiscal year 2024. The increase primarily due to the increase in professional service fees paid to outsourced consultants for promoting the Company's brand and internet medical platform of approximatelyRMB36.5 million (US ) and service fees to doctors and staff costs which is in line of the increase in the revenues from Internet hospital business.$5.2 million - General and administrative expenses were
RMB59.7 million (US ) in fiscal year 2025, increased by$8.5 million 402.9% fromRMB11.9 million in fiscal year 2024. The increase primarily due to (i) increase in professional service fee paid to outsourced consultants for consultancy for investor relationship management of approximatelyRMB38.0 million (US ) incurred in fiscal year 2025; and (ii) the increase in consulting service fee and office fees of$5.4 million RMB6.5 million (US ) paid during the process of initial public offering, primarily offset by the decrease in expected credit loss recognized resulting from the efforts for collection of accounts receivable.$0.9 million - Research and development expenses were
RMB12.9 million (US ) in fiscal year 2025, increased by$1.8 million 328.5% fromRMB3.0 million in fiscal year 2024. The increase primarily due to a new research and development project, especially in AI and healthcare-related AI applications, launched in fiscal year 2025 and related consulting service fee paid. - Impairment loss on property and equipment and operating lease right-of-use assets with definite lives of
RMB2.2 million andRMB2.1 million (US ) in fiscal year 2024 and 2025, respectively.$0.3 million
Net Loss
Net loss was RMB130.9 million (
Basic and Diluted Loss per Share
Basic and diluted loss per share were RMB21.96 (
Financial Condition
As of December 31, 2025, the Company had cash and cash equivalents of RMB9.6 million (
Net cash used in operating activities in fiscal year 2025 was RMB148.5 million (
Net cash used in investing activities in fiscal year 2025 was RMB1.6 million (
Net cash provided by financing activities in fiscal year 2025 was RMB153.9 million (
Exchange Rate Information
This announcement contains translations of certain RMB amounts into
Recent Development
On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
POMDOCTOR LIMITED
CONSOLIDATED BALANCE SHEETS
December 31, 2024 | December 31, 2025 | December 31, 2025 | ||||||||||||||||||||||||
RMB | RMB | US$ | ||||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||
Current assets: | ||||||||||||||||||||||||||
Cash and cash equivalents (including amounts of the consolidated VIEs of | 7,651,695 | 9,580,367 | 1,369,974 | |||||||||||||||||||||||
Accounts receivable, net (including amounts of the consolidated VIEs of | 8,374,608 | 18,440,482 | 2,636,954 | |||||||||||||||||||||||
Accounts receivable - a related party (including amounts of the consolidated VIEs of | 424,259 | 831,436 | 118,894 | |||||||||||||||||||||||
Amount due from related parties (including amounts of the consolidated VIEs of | 5,632,987 | 3,637,039 | 520,090 | |||||||||||||||||||||||
Inventories (including amounts of the consolidated VIEs of | 9,165,973 | 8,280,145 | 1,184,045 | |||||||||||||||||||||||
Other receivables, net (including amounts of the consolidated VIEs of | 5,318,724 | 63,517,961 | 9,082,948 | |||||||||||||||||||||||
Advances to suppliers (including amounts of the consolidated VIEs of | 929,167 | 679,196 | 97,124 | |||||||||||||||||||||||
Total current assets | 37,497,413 | 104,966,626 | 15,010,029 | |||||||||||||||||||||||
Property and equipment, net (including amounts of the consolidated VIEs of | 461,362 | 1,246,568 | 178,257 | |||||||||||||||||||||||
Other non-current assets (including amounts of the consolidated VIEs of | 831,132 | 1,344,232 | 192,223 | |||||||||||||||||||||||
Deferred offering costs (including amounts of the consolidated VIEs of | 7,437,679 | — | — | |||||||||||||||||||||||
Total non-current assets | 8,730,173 | 2,590,800 | 370,480 | |||||||||||||||||||||||
Total assets | 46,227,586 | 107,557,426 | 15,380,509 | |||||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Current liabilities: | ||||||||||||||||||||||||||
Accounts payable (including amounts of the consolidated VIEs of | 25,320,486 | 44,813,902 | 6,408,303 | |||||||||||||||||||||||
Accounts payable – a related party (including amounts of the consolidated VIEs of | 25,891 | 7,296 | 1,043 | |||||||||||||||||||||||
Short-term bank loans (including amounts of the consolidated VIEs of | 34,958,333 | 53,000,000 | 7,578,899 | |||||||||||||||||||||||
Long-term bank loans, current (including amounts of the consolidated VIEs of | 300,000 | 3,700,000 | 529,093 | |||||||||||||||||||||||
Long-term loans, current (including amounts of the consolidated VIEs of | 10,000,000 | 10,000,000 | 1,429,981 | |||||||||||||||||||||||
Long-term loans from third parties, current (including amounts of the consolidated VIEs of | 2,320,082 | 200,000 | 28,600 | |||||||||||||||||||||||
Salary and welfare payable (including amounts of the consolidated VIEs of | 15,375,537 | 14,477,975 | 2,070,323 | |||||||||||||||||||||||
Advance from customers (including amounts of the consolidated VIEs of | 1,756,046 | 1,591,131 | 227,529 | |||||||||||||||||||||||
Value added tax ("VAT") and other tax payable (including amounts of the consolidated VIEs of | 815,462 | 658,983 | 94,233 | |||||||||||||||||||||||
Other payables (including amounts of the consolidated VIEs of | 12,888,750 | 11,817,379 | 1,689,865 | |||||||||||||||||||||||
Accrued liabilities (including amounts of the consolidated VIEs of | 9,712,966 | 14,580,658 | 2,085,008 | |||||||||||||||||||||||
Short-term loans from third parties (including amounts of the consolidated VIEs of | 11,551,614 | 610,637 | 87,320 | |||||||||||||||||||||||
Loans from related parties, current (including amounts of the consolidated VIEs of | 13,821,875 | 15,198,309 | 2,173,329 | |||||||||||||||||||||||
Amount due to related parties (including amounts of the consolidated VIEs of | 36,829,010 | 45,966,864 | 6,573,174 | |||||||||||||||||||||||
Operating lease liabilities, current (including amounts of the consolidated VIEs of | 1,388,863 | 1,545,002 | 220,932 | |||||||||||||||||||||||
Other current liabilities (including amounts of the consolidated VIEs of | 2,080,556 | — | — | |||||||||||||||||||||||
Total current liabilities | 179,145,471 | 218,168,136 | 31,197,632 | |||||||||||||||||||||||
Long-term bank loans, noncurrent (including amounts of the consolidated VIEs of | 8,400,000 | 11,000,000 | 1,572,979 | |||||||||||||||||||||||
Long-term loans from third parties, noncurrent (including amounts of the consolidated VIEs of nil and | — | 2,000,582 | 286,079 | |||||||||||||||||||||||
Loans from related parties, noncurrent (including amounts of the consolidated VIEs of | 356,690,859 | 356,390,859 | 50,963,215 | |||||||||||||||||||||||
Operating lease liabilities, noncurrent (including amounts of the consolidated VIEs of | 1,672,218 | 1,294,510 | 185,112 | |||||||||||||||||||||||
Total non-current liabilities | 366,763,077 | 370,685,951 | 53,007,385 | |||||||||||||||||||||||
Total liabilities | 545,908,548 | 588,854,087 | 84,205,017 | |||||||||||||||||||||||
Commitments and contingencies | — | — | — | |||||||||||||||||||||||
Mezzanine equity | ||||||||||||||||||||||||||
Convertible redeemable preferred shares ( | 1,595,051,558 | — | — | |||||||||||||||||||||||
Redeemable non-controlling interests | 168,671,234 | — | — | |||||||||||||||||||||||
Total mezzanine equity | 1,763,722,792 | — | — | |||||||||||||||||||||||
Deficit | ||||||||||||||||||||||||||
Class A Ordinary shares ( | 2,988 | 14,997 | 2,145 | |||||||||||||||||||||||
Class B Ordinary shares ( | 1,408 | 1,408 | 201 | |||||||||||||||||||||||
Subscription receivable | (1,608 | ) | (2,186 | ) | (313 | ) | ||||||||||||||||||||
Additional paid-in capital | — | 2,023,765,569 | 289,394,627 | |||||||||||||||||||||||
Accumulated deficit | (2,263,419,477 | ) | (2,475,998,594 | ) | (354,063,090 | ) | ||||||||||||||||||||
Accumulated other comprehensive (loss) | (5,231 | ) | (1,752,460 | ) | (250,598 | ) | ||||||||||||||||||||
Total Pomdoctor Limited's shareholders' deficit | (2,263,421,920 | ) | (453,971,266 | ) | (64,917,028 | ) | ||||||||||||||||||||
Noncontrolling interests | 18,166 | (27,325,395 | ) | (3,907,480 | ) | |||||||||||||||||||||
Total deficit | (2,263,403,754 | ) | (481,296,661 | ) | (68,824,508 | ) | ||||||||||||||||||||
Total liabilities, mezzanine equity and deficit | 46,227,586 | 107,557,426 | 15,380,509 | |||||||||||||||||||||||
* | Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for the Reorganization completed on August 8, 2024. |
POMDOCTOR LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
For the Years Ended December 31, | ||||||||||||||||
2023 | 2024 | 2025 | 2025 | |||||||||||||
RMB | RMB | RMB | US$ | |||||||||||||
Net revenues – third parties | 304,729,898 | 341,328,781 | 399,359,702 | 57,107,678 | ||||||||||||
Net revenues – a related party | 123,073 | 1,229,139 | 555,262 | 79,401 | ||||||||||||
Net revenues | 304,852,971 | 342,557,920 | 399,914,964 | 57,187,079 | ||||||||||||
Cost of revenues | 266,131,202 | 294,863,867 | 347,632,853 | 49,710,837 | ||||||||||||
Gross profit | 38,721,769 | 47,694,053 | 52,282,111 | 7,476,242 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing expenses (including related party amounts of nil, nil and | 43,678,681 | 56,366,433 | 96,214,406 | 13,758,477 | ||||||||||||
General and administrative expenses | 12,314,018 | 11,878,335 | 59,729,352 | 8,541,184 | ||||||||||||
Research and development expenses | 3,370,945 | 3,002,040 | 12,864,656 | 1,839,621 | ||||||||||||
Impairment loss on long-lived assets | 1,107,027 | 2,238,525 | 2,108,517 | 301,514 | ||||||||||||
Impairment loss on long-term investment | 500,000 | — | — | — | ||||||||||||
Total operating expenses | 60,970,671 | 73,485,333 | 170,916,931 | 24,440,796 | ||||||||||||
Loss from operations | (22,248,902 | ) | (25,791,280 | ) | (118,634,820 | ) | (16,964,554 | ) | ||||||||
Other expense, net: | ||||||||||||||||
Other income | 163,622 | 1,238,538 | 496,122 | 70,945 | ||||||||||||
Other expense | (1,336,595 | ) | (37,608 | ) | (60,325 | ) | (8,625 | ) | ||||||||
Interest expense (including related party amounts of | (13,849,119 | ) | (12,964,584 | ) | (12,885,122 | ) | (1,842,548 | ) | ||||||||
Government grants | 321,573 | 189,500 | 152,599 | 21,821 | ||||||||||||
Total other expense, net | (14,700,519 | ) | (11,574,154 | ) | (12,296,726 | ) | (1,758,407 | ) | ||||||||
Loss before income tax | (36,949,421 | ) | (37,365,434 | ) | (130,931,546 | ) | (18,722,961 | ) | ||||||||
Income tax expense | — | — | (375 | ) | (54 | ) | ||||||||||
Net loss | (36,949,421 | ) | (37,365,434 | ) | (130,931,921 | ) | (18,723,015 | ) | ||||||||
Accretion to redemption value of mezzanine equity | (108,440,354 | ) | (105,969,614 | ) | (81,648,716 | ) | (11,675,611 | ) | ||||||||
Less: Net income (loss) attributable to noncontrolling interests | 1,057 | 25,878 | (1,520 | ) | (217 | ) | ||||||||||
Net loss attributable to the Pomdoctor Limited's ordinary shareholders | (145,390,832 | ) | (143,360,926 | ) | (212,579,117 | ) | (30,398,409 | ) | ||||||||
Net loss | (36,949,421 | ) | (37,365,434 | ) | (130,931,921 | ) | (18,723,015 | ) | ||||||||
Other comprehensive loss: | ||||||||||||||||
Foreign currency translation adjustments, net of nil income taxes | — | (5,231 | ) | (1,747,229 | ) | (249,850 | ) | |||||||||
Total comprehensive loss | (36,949,421 | ) | (37,370,665 | ) | (132,679,150 | ) | (18,972,865 | ) | ||||||||
Accretion to redemption value of mezzanine equity | (108,440,354 | ) | (105,969,614 | ) | (81,648,716 | ) | (11,675,611 | ) | ||||||||
Less: comprehensive income (loss) attributable to noncontrolling interests | 1,057 | 25,878 | (1,520 | ) | (217 | ) | ||||||||||
Comprehensive loss attributable to the Pomdoctor Limited's ordinary shareholders | (145,390,832 | ) | (143,366,157 | ) | (214,326,346 | ) | (30,648,259 | ) | ||||||||
Loss per share | ||||||||||||||||
Basic and diluted | (23.04 | ) | (22.72 | ) | (21.96 | ) | (3.14 | ) | ||||||||
Weighted average number of ordinary shares outstanding* | ||||||||||||||||
Basic and diluted | 6,310,198 | 6,310,198 | 9,680,622 | 9,680,622 | ||||||||||||
* | Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for the Reorganization completed on August 8, 2024. |
POMDOCTOR LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended December 31, | |||||||||||||||||||||||||||||
2023 | 2024 | 2025 | 2025 | ||||||||||||||||||||||||||
RMB | RMB | RMB | US$ | ||||||||||||||||||||||||||
Cash flows from operating activities: | |||||||||||||||||||||||||||||
Net loss | (36,949,421 | ) | (37,365,434 | ) | (130,931,921 | ) | (18,723,015 | ) | |||||||||||||||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||||||||||||||||
Depreciation of property and equipment | 112,092 | 134,510 | 149,307 | 21,351 | |||||||||||||||||||||||||
Change in expected credit losses | 1,488,459 | 841,683 | (240,982 | ) | (34,460 | ) | |||||||||||||||||||||||
Allowance for inventory | 503,079 | 494,459 | 1,883,635 | 269,355 | |||||||||||||||||||||||||
Share base payment | — | — | 16,423,683 | 2,348,555 | |||||||||||||||||||||||||
Impairment loss on long-lived assets | 1,107,027 | 2,238,525 | 2,108,517 | 301,514 | |||||||||||||||||||||||||
Impairment loss on long-term investment | 500,000 | — | — | — | |||||||||||||||||||||||||
Gain/(Loss) on disposal of property and equipment | — | (3,893 | ) | — | — | ||||||||||||||||||||||||
Changes in operating assets and liabilities: | |||||||||||||||||||||||||||||
Accounts receivable | (1,273,526 | ) | 20,309,367 | (10,099,387 | ) | (1,444,193 | ) | ||||||||||||||||||||||
Accounts receivable – a related party | — | (424,259 | ) | (407,177 | ) | (58,226 | ) | ||||||||||||||||||||||
Amount due from related parties | 831,665 | (3,229,309 | ) | 1,995,948 | 285,417 | ||||||||||||||||||||||||
Inventories | (5,001,966 | ) | 3,033,987 | (997,807 | ) | (142,684 | ) | ||||||||||||||||||||||
Other receivables | (4,011,854 | ) | (210,043 | ) | (57,924,742 | ) | (8,283,128 | ) | |||||||||||||||||||||
Advances to suppliers | (53,696 | ) | 1,950,808 | 249,971 | 35,745 | ||||||||||||||||||||||||
Other non-current assets | (171,874 | ) | (281,632 | ) | 86,900 | 12,427 | |||||||||||||||||||||||
Accounts payable | (1,627,218 | ) | (16,254,687 | ) | 19,493,416 | 2,787,521 | |||||||||||||||||||||||
Accounts payable – a related party | (30,908 | ) | (88,034 | ) | (18,595 | ) | (2,659 | ) | |||||||||||||||||||||
Salary and welfare payable | (3,400,663 | ) | 149,452 | (897,562 | ) | (128,350 | ) | ||||||||||||||||||||||
Advance from customers | (1,489,222 | ) | 512,618 | (164,915 | ) | (23,583 | ) | ||||||||||||||||||||||
Value added tax ("VAT") and other tax payable | (115,371 | ) | 601,150 | (156,479 | ) | (22,376 | ) | ||||||||||||||||||||||
Other payables | (3,001,148 | ) | 3,391,790 | 1,300,394 | 185,954 | ||||||||||||||||||||||||
Accrued liabilities | (96,449 | ) | (82,393 | ) | 4,867,692 | 696,071 | |||||||||||||||||||||||
Amount due to related parties | 8,879,617 | 7,145,948 | 9,137,854 | 1,306,696 | |||||||||||||||||||||||||
Operating lease liabilities | (1,994,305 | ) | (1,076,049 | ) | (2,256,846 | ) | (322,725 | ) | |||||||||||||||||||||
Refund liability | — | 2,080,556 | (2,080,556 | ) | (297,516 | ) | |||||||||||||||||||||||
Net cash used in operating activities | (45,795,682 | ) | (16,130,880 | ) | (148,479,652 | ) | (21,232,309 | ) | |||||||||||||||||||||
Cash flows from investing activities: | |||||||||||||||||||||||||||||
Payment for purchase of property and equipment | (111,891 | ) | (37,773 | ) | (1,007,753 | ) | (144,107 | ) | |||||||||||||||||||||
Payment for other noncurrent assets | — | — | (600,000 | ) | (85,799 | ) | |||||||||||||||||||||||
Proceeds from disposal of property and equipment | — | 4,400 | — | — | |||||||||||||||||||||||||
Net cash used in investing activities | (111,891 | ) | (33,373 | ) | (1,607,753 | ) | (229,906 | ) | |||||||||||||||||||||
Cash flows from financing activities: | |||||||||||||||||||||||||||||
Loans from related parties | 104,430,113 | 15,301,351 | 24,778,594 | 3,543,292 | |||||||||||||||||||||||||
Repayment to related parties | (64,460,091 | ) | (25,047,012 | ) | (23,702,159 | ) | (3,389,364 | ) | |||||||||||||||||||||
Proceeds from short-term bank loans | 28,000,000 | 44,100,000 | 56,000,000 | 8,007,893 | |||||||||||||||||||||||||
Repayment of short-term bank loans | (15,664,494 | ) | (31,141,667 | ) | (37,958,333 | ) | (5,427,969 | ) | |||||||||||||||||||||
Proceeds from long-term bank loans | 3,000,000 | 6,000,000 | 7,000,000 | 1,000,987 | |||||||||||||||||||||||||
Repayment of long-term bank loans | — | (847,295 | ) | (1,000,000 | ) | (142,998 | ) | ||||||||||||||||||||||
Repayment of long-term loans | (470,272 | ) | (391,667 | ) | (119,500 | ) | (17,088 | ) | |||||||||||||||||||||
Loans from third parties | 1,124,048 | 19,856,630 | 2,951,275 | 422,027 | |||||||||||||||||||||||||
Repayment to third parties | (3,615,200 | ) | (10,814,260 | ) | (13,892,252 | ) | (1,986,566 | ) | |||||||||||||||||||||
Proceeds from IPO | — | — | 163,932,614 | 23,442,052 | |||||||||||||||||||||||||
Payment for deferred offering cost | (2,276,926 | ) | — | (24,063,528 | ) | (3,441,039 | ) | ||||||||||||||||||||||
Net cash provided by financing activities | 50,067,178 | 17,016,080 | 153,926,711 | 22,011,227 | |||||||||||||||||||||||||
Effect of exchange rate changes | — | (5,231 | ) | (1,910,634 | ) | (273,217 | ) | ||||||||||||||||||||||
Net increase in cash and cash equivalents and restricted cash | 4,159,605 | 846,596 | 1,928,672 | 275,796 | |||||||||||||||||||||||||
Cash and cash equivalents and restricted cash at beginning of the year | 2,645,494 | 6,805,099 | 7,651,695 | 1,094,178 | |||||||||||||||||||||||||
Cash and cash equivalents and restricted cash at end of the year | 6,805,099 | 7,651,695 | 9,580,367 | 1,369,974 | |||||||||||||||||||||||||
Including: | |||||||||||||||||||||||||||||
Cash and cash equivalents at beginning of the year | 2,485,598 | 6,717,031 | 7,651,695 | 1,094,178 | |||||||||||||||||||||||||
Restricted cash at beginning of the year | 159,896 | 88,068 | — | — | |||||||||||||||||||||||||
Cash and cash equivalents and restricted cash at end of the year | 6,805,099 | 7,651,695 | 9,580,367 | 1,369,974 | |||||||||||||||||||||||||
Including: | |||||||||||||||||||||||||||||
Cash and cash equivalents at end of the year | 6,717,031 | 7,651,695 | 9,580,367 | 1,369,974 | |||||||||||||||||||||||||
Restricted cash at end of the year | 88,068 | — | — | — | |||||||||||||||||||||||||
Supplemental disclosures of cash flows information: | |||||||||||||||||||||||||||||
Cash paid for income tax | — | — | — | — | |||||||||||||||||||||||||
Cash paid for interest expense | 2,388,025 | 2,744,793 | 2,703,601 | 386,610 | |||||||||||||||||||||||||
Supplemental disclosure of noncash investing and financing activities: | |||||||||||||||||||||||||||||
Property and equipment acquired by assuming a long-term loan | 640,000 | — | — | — | |||||||||||||||||||||||||
Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | 1,063,104 | 2,200,752 | 2,035,277 | 291,041 | |||||||||||||||||||||||||
Conversion of convertible redeemable preferred shares into Class A ordinary shares upon IPO | — | — | 1,668,974,247 | 238,660,143 | |||||||||||||||||||||||||
Conversion of convertible redeemable non-controlling interest into non-controlling interest upon IPO | — | — | 176,397,261 | 25,224,473 | |||||||||||||||||||||||||
Reclassification of deferred offering costs to additional paid-in capital | — | — | 29,129,441 | 4,165,455 | |||||||||||||||||||||||||
Expensed of deferred offering costs before IPO | — | — | 1,624,680 | 232,326 | |||||||||||||||||||||||||
Net off deferred offering costs to other payable | — | — | 747,087 | 106,832 | |||||||||||||||||||||||||
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-fiscal-year-2025-financial-results-302772516.html
SOURCE POMDOCTOR LIMITED